Markets:

Overview

News

Currencies

International

Treasuries

Ascendis Pharma A/S - Ordinary Share (NQ:ASND)

217.01 -1.83 (-0.83%)

Streaming Delayed Price Updated: 9:43 AM EDT, Jun 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ascendis Pharma A/S - Ordinary Share

< Previous 1 2 3 4 5 6 7 8 9 Next >

How Do Investors Really Feel About Ascendis Pharma? ↗

August 28, 2025

Via Benzinga

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today ↗

August 19, 2025

Via Benzinga

Ascendis (ASND) Q2 2025 Earnings Call Transcript ↗

August 07, 2025

Via The Motley Fool

Topics Earnings

Earnings Scheduled For August 7, 2025 ↗

August 07, 2025

Via Benzinga

What's Driving the Market Sentiment Around Ascendis Pharma? ↗

August 06, 2025

Via Benzinga

What's Driving the Market Sentiment Around Ascendis Pharma? ↗

August 04, 2025

Via Benzinga

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today ↗

July 28, 2025

Via Benzinga

Peering Into Ascendis Pharma's Recent Short Interest ↗

July 03, 2025

Via Benzinga

Is Ascendis Pharma Gaining or Losing Market Support? ↗

June 03, 2025

Via Benzinga

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today ↗

May 29, 2025

Via Benzinga

Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today ↗

July 22, 2025

Via Benzinga

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today ↗

July 07, 2025

Via Benzinga

$100 Invested In This Stock 10 Years Ago Would Be Worth This Much Today ↗

June 12, 2025

Via Benzinga

If You Invested $100 In This Stock 10 Years Ago, You Would Have This Much Today ↗

May 21, 2025

Via Benzinga

Here's How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 15 Years ↗

May 06, 2025

Via Benzinga

This Twilio Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday ↗

May 05, 2025

Via Benzinga

Earnings Scheduled For May 1, 2025 ↗

May 01, 2025

Via Benzinga

A Glimpse of Ascendis Pharma's Earnings Potential ↗

April 30, 2025

Via Benzinga

If You Invested $1000 In This Stock 15 Years Ago, You Would Have This Much Today ↗

March 04, 2025

Via Benzinga

Why ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) could fit Mark Minervini’s high-growth criteria ↗

April 28, 2025

A fundamental and technical analysis of (NASDAQ:ASND): Is ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) suited for high growth investing?

Via Chartmill

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today ↗

April 15, 2025

Via Benzinga

Does ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) show the characteristics of a Minervini super stock? ↗

April 04, 2025

A fundamental and technical analysis of (NASDAQ:ASND): Why the high growth investor may take a look at ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND).

Via Chartmill

Looking Into Ascendis Pharma's Recent Short Interest ↗

March 26, 2025

Via Benzinga

Here's How Much $100 Invested In Ascendis Pharma 15 Years Ago Would Be Worth Today ↗

March 25, 2025

Via Benzinga

Is ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND) a Minervini-style stock? ↗

March 14, 2025

A fundamental and technical analysis of (NASDAQ:ASND): Why the high growth investor may take a look at ASCENDIS PHARMA A/S - ADR (NASDAQ:ASND).

Via Chartmill

Here's How Much $100 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today ↗

February 19, 2025

Via Benzinga

Earnings Scheduled For February 12, 2025 ↗

February 12, 2025

Via Benzinga

Why Is BioMarin Stock Trading Higher On Thursday? ↗

February 20, 2025

BioMarin exceeded Q4 earnings expectations, raised 2025 guidance, and projected strong Voxzogo growth. Analysts increased price targets following the results.

Via Benzinga

Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday? ↗

February 13, 2025

Ascendis Pharma beat Q4 earnings and revenue estimates, driven by a $100M Novo Nordisk deal and Yorvipath's EU launch. Goldman Sachs raised its price target.

Via Benzinga

Ascendis Pharma Eyes Best Open In A Month After Q4 Print, But BofA Cuts Price Target: Retail Gets Buzzing ↗

February 13, 2025

The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp.

Via Stocktwits

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.